Current disease modifying approaches to treat Parkinson's disease

Show full item record



Permalink

http://hdl.handle.net/10138/223922

Citation

Lindholm , D , Mäkelä , J , Di Liberto , V , Mudo , G , Belluardo , N , Eriksson-Rosenberg , O & Saarma , M 2016 , ' Current disease modifying approaches to treat Parkinson's disease ' , Cellular and Molecular Life Sciences , vol. 73 , no. 7 , pp. 1365-1379 . https://doi.org/10.1007/s00018-015-2101-1

Title: Current disease modifying approaches to treat Parkinson's disease
Author: Lindholm, Dan; Mäkelä, Johanna; Di Liberto, Valentina; Mudo, Giuseppa; Belluardo, Natale; Eriksson-Rosenberg, Ove; Saarma, Mart
Contributor organization: Medicum
Dan Bj Lindholm / Principal Investigator
Department of Biochemistry and Developmental Biology
Ove Eriksson-Rosenberg / Principal Investigator
Institute of Biotechnology
Mart Saarma / Principal Investigator
Date: 2016-04
Language: eng
Number of pages: 15
Belongs to series: Cellular and Molecular Life Sciences
ISSN: 1420-682X
DOI: https://doi.org/10.1007/s00018-015-2101-1
URI: http://hdl.handle.net/10138/223922
Abstract: Parkinson's disease (PD is a progressive neurological disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients. The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the molecular mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies. Neurotrophic factors are by virtue of their survival promoting activities attract candidates to counteract and possibly halt cell degeneration in PD. In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown positive results in protecting and repairing dopaminergic neurons in various models of PD. Other substances with trophic actions in dopaminergic neurons include neuropeptides and small compounds that target different pathways impaired in PD, such as increased cell stress, protein handling defects, dysfunctional mitochondria and neuroinflammation. In this review, we will highlight the recent developments in this field with a focus on trophic factors and substances having the potential to beneficially influence the viability and functions of dopaminergic neurons as shown in preclinical or in animal models of PD.
Subject: Neurotrophic factors
Neuropeptides
Dopamine neurons
alpha-Synuclein
ER stress
Mitochondria
Protein aggregation
Neuroinflammation
CYCLASE-ACTIVATING POLYPEPTIDE
ENDOPLASMIC-RETICULUM STRESS
FIBROBLAST-GROWTH-FACTOR
CATECHOLAMINERGIC NEURON SURVIVAL
MIDBRAIN DOPAMINERGIC-NEURONS
UNFOLDED PROTEIN RESPONSE
ALPHA-SYNUCLEIN TOXICITY
BLOOD-BRAIN-BARRIER
NEUROTROPHIC FACTOR
IN-VIVO
3111 Biomedicine
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Current_disease_modifying_approaches.pdf 774.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record